VEGFA and colitis: Attempts have been made to reduce angiogenesis and reduce colitis symptoms by targeting diverse molecular pathways, such as VEGF, TSP1/CD36, and CD40‐CD40L, with limited success (Danese et al, 2007a,b; Punekar et al, 2008; Scaldaferri et al, 2009).